Noxopharm Ltd. (AU:NOX) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Noxopharm Limited announces the upcoming expiry of two sets of unlisted options, with deadlines on 6th November and 15th December 2024, urging option holders to submit exercise forms and payments by the specified dates. The Australian biotech firm, known for its cancer and inflammation treatments as well as its stake in Nyrada Inc, reminds investors of its innovative focus on drug development and mRNA vaccine enhancement technologies.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.